Standard BioTools (LAB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order virtually, allowing broader stockholder participation and inclusivity.
Attendees included board members, executive officers, legal counsel, auditors, and the Inspector of Election.
The agenda included formal business, voting on proposals, and a Q&A session at the end.
Corporate governance
Notice of the meeting and proxy materials were duly provided to all stockholders of record.
A quorum was confirmed, enabling the meeting to proceed with official business.
Voting was conducted by proxy and via the web portal, with each share entitled to one vote.
Board and executive committee updates
Three Class I directors were nominated for election to serve until the 2029 Annual Meeting.
The board recommended approval of all proposals, including director elections and compensation matters.
Latest events from Standard BioTools
- Q2 2026 revenue fell 8% year-over-year, but gross margin rose to 52.4% and EBITDA loss narrowed.LAB
Q2 2026 - All-stock merger forms a $900M+ cash biopharma with a deep pipeline and new leadership.LAB
M&A announcement - Q1 2026 revenue grew 5% to $21.1M, with net income surging on a major asset sale.LAB
Q1 2026 - 2026 meeting features director elections, key compensation votes, and new equity plan approval.LAB
Proxy filing - Key votes include director elections, executive pay, auditor ratification, and equity plan changes.LAB
Proxy filing - 2025 revenue declined, but margins and net income improved, with strong cash post-divestiture.LAB
Q4 2025 - Q3 2024 revenue was $45M, with improved margins and accelerated merger synergies.LAB
Q3 2024 - Q1 2025 revenue fell 10% to $40.8M, but cost cuts and improved margins narrowed losses.LAB
Q1 2025 - Cost synergies and consumables growth offset revenue declines, supporting a strong 2025 outlook.LAB
Q4 2024